4E2.F RELMADA THERAPEUT.DL-001

Healthcare Biotechnology Frankfurt Exchange
- EUR
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Is 4E2.F undervalued?

Graham number

The Graham number of RELMADA THERAPEUT.DL-001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

RELMADA THERAPEUT.DL-001 fundamental analysis

No fundamental analysis for RELMADA THERAPEUT.DL-001 yet.

RELMADA THERAPEUT.DL-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About RELMADA THERAPEUT.DL-001

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, touret…

Full company profile